Please login to the form below

Not currently logged in
Email:
Password:

Glenmark settles with Astellas/ Triax

Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin

India-based generics manufacturer Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin.

The suit relates to an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a form of hydrocortisone butyrate cream, Glenmark's generic equivalent of Locoid Lipocream, currently registered by Astellas and licensed to Triax.

Under the settlement and licence agreement, Glenmark will be permitted to market and distribute its version of the cream under a royalty-bearing licence from Astellas and Triax in the US by the end of 2013.

In a statement, Glenmark said it believed it was entitled to 180 days of exclusivity to market the product as the first generic company to file a related ANDA.

According to IMS Health data, Locoid Lipocream had sales of around $38m for 2010.

25th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....